HOME >> MEDICINE >> NEWS
International breast cancer prevention study launches in the United States and Canada

Boston-March 30, 2005 Today, a new clinical trial evaluating a novel approach to breast cancer prevention launched in the United States and Canada. Called the ExCel research study, this is the first North American clinical trial to evaluate the role of an aromatase inhibitor in the prevention of breast cancer.

Coordinated by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), the ExCel research study will examine the potential benefit of exemestane and its ability to prevent breast cancer in women who are at increased risk for the disease. Exemestane part of a class of drugs called aromatase inhibitors suppresses estrogen production, a key component in the development of some types of breast cancer. Exemestane could provide women with an alternative option to tamoxifen, the only drug FDA approved for prevention of breast cancer.

"Breast cancer is a major public health issue every 30 seconds somewhere in the world a woman is diagnosed with this disease," says Dr. Paul Goss, the ExCel research study chair.

"Thousands of women have already beat breast cancer thanks to recent research on aromatase inhibitors. As a result, we think this could be an effective approach to preventing it from developing in the first place."

The ExCel research study will follow more than 4,500 postmenopausal women from the U.S., Canada and Spain over a five year period. To be eligible, women must be 35 years of age or older and have an increased risk of developing breast cancer. Risk factors can include a woman's age, her family history of breast cancer, her age at first menstrual period and her age at first live birth.

Initial results of the trial could be available within four years and study investigators hope to see as much as a two-thirds reduction in the incidence of breast cancer among women in the treatment group.

Aromatase inhibitors are currently being used to treat breast cancer in wo
'"/>

Contact: Samantha Kaplan
samantha.kaplan@edelman.com
312-297-7439
Edelman Public Relations
30-Mar-2005


Page: 1 2 3 4

Related medicine news :

1. National Academies advisory: May 2 Symposium on International Science Policy
2. Awards & fellowships at the International & American Association for Dental Research General Session
3. Lectures, keynoters, symposia highlight International Dental Research meeting
4. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
5. International gathering of experts to share retinoblastoma breakthroughs
6. International trial of two microbicides begins
7. International gathering at UH examines top computer code
8. International trial finds benefits of breast MRI in women at high risk
9. International study provides culture-by-culture clues to family violence and abuse
10. St. Jude scientist wins International Society of Experimental Hematology award
11. International MRC trial finds a routine treatment for head injury may do more harm than good

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult with gluten intolerance ... you may be interested in participating in a research study that focuses on family ... understand more about the relational aspects of adults who have gluten sensitivities who cohabitate ...
(Date:8/19/2017)... York (PRWEB) , ... August 19, 2017 , ... ... has announced that it is the first organization with pending recognition status from ... Diabetes Prevention Program (“DPP”) via group telehealth classes and live video conferencing. ...
(Date:8/19/2017)... Fla. (PRWEB) , ... August 19, 2017 , ... ... Taufiq Ahmed, M.D., has joined its Orlando location as an interventional pain management ... anesthesiology, a focus on the treatment of migraine headaches, and significant experience in ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... specialized asset-light logistics provider of complex transport solutions for mission-critical and non-discretionary ... Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: RRTS). ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance ... a new charity drive to generate community support for efforts to educate the local ... and treatments for all types of cancer. , Each day in America, roughly ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
Breaking Medicine Technology:
Cached News: